Form 4: Akebia CEO Buys Shares, Resolves Short-Swing Profit

Akebia Therapeutics CEO John P. Butler acquired 69,270 shares of common stock, simultaneously resolving a short-swing profit issue related to a prior sell-to-cover transaction.

Summary

• John P. Butler, CEO and President of Akebia Therapeutics, Inc. (AKBA), acquired 69,270 shares of common stock on March 4, 2026.
• The shares were purchased at a weighted average price of $1.25 per share, with individual transaction prices ranging from $1.23 to $1.28.
• Following this transaction, Butler directly owns 3,367,064 shares and indirectly owns 159,928 shares through the Dorothy Butler Revocable Trust.
• This purchase was matchable under Section 16(b) of the Securities Exchange Act of 1934 with a previous sale of 341,305 shares of Akebia common stock on February 2, 2026, at a price of $1.39 per share.
• The prior sale was executed pursuant to an automatic sell-to-cover instruction solely to cover applicable withholding taxes in connection with the vesting of RSUs granted on January 31, 2023, 2024, and 2025.
• Butler has paid Akebia $9,664.60, representing the full amount of the profit realized from the short-swing transaction.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal due to the insider purchase, which indicates management confidence, tempered by the need to resolve a short-swing profit issue, though this was handled compliantly.

Positives

• CEO John P. Butler increased his direct beneficial ownership in Akebia Therapeutics by 69,270 shares, which can signal confidence in the company's future.
• The reporting person proactively resolved a Section 16(b) short-swing profit issue by paying $9,664.60 to the company, demonstrating adherence to regulatory compliance.

Negatives

• The necessity to resolve a Section 16(b) short-swing profit issue indicates a potential oversight in transaction planning, even if subsequently resolved.
• The prior 'sell-to-cover' transaction involved a disposition of a larger number of shares (341,305) at a higher price ($1.39) than the current acquisition, which could be viewed as a net reduction in beneficial ownership from recent activity.

Risks

• Potential for future Section 16(b) short-swing profit issues if insider trading policies and transaction planning are not meticulously managed, although this specific instance was resolved.
• The underlying reason for the prior sale was to cover taxes on RSU vesting, which, while legitimate, can sometimes be misinterpreted as a lack of confidence by some investors.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider purchases, even relatively small ones, can signal management confidence and alignment with shareholder interests. The context of a 'sell-to-cover' transaction for RSU vesting is a common practice for executives to manage tax obligations, and the proactive resolution of a Section 16(b) issue demonstrates a commitment to regulatory compliance, which is standard for publicly traded companies.

Comparison to Industry Standards

• Insider purchases are generally viewed positively across industries, as they align the interests of management with those of shareholders.
• The resolution of a Section 16(b) short-swing profit issue, while a technical compliance matter, demonstrates the company's and executive's commitment to regulatory adherence, which is a standard expectation for publicly traded companies.
• 'Sell-to-cover' transactions for RSU vesting are a common practice across industries for executives to manage tax obligations without needing to liquidate other assets.

Stakeholder Impact

• Shareholders: The insider purchase could be seen as a positive signal of confidence from the CEO. The resolution of the short-swing profit issue ensures regulatory compliance and protects shareholder interests by recovering the profit.
• Regulatory Authorities: The filing demonstrates compliance with Section 16(a) reporting requirements and the resolution of a Section 16(b) issue.

Key Dates

Recommendation

The insider purchase by the CEO is a positive indicator of confidence, but the transaction size is not substantial enough to warrant a 'buy' recommendation on its own. The resolution of the short-swing profit issue demonstrates compliance but also highlights a past oversight. Investors should 'hold' and monitor broader company performance and strategic developments rather than making a decision solely based on this routine insider filing.

Keywords

Akebia Therapeutics, AKBA, John P. Butler, Insider Trading, Form 4, Section 16(b), Short-Swing Profit, Stock Purchase, CEO, Common Stock, RSU, Sell-to-cover